How ridiculous and uninformed it is to think that posting about other companies, whose platforms and drugs will benefit tremendously from lenz, have no bearing on this company. It's understandable that people may think that posting about other companies on this board doesn't belong here. But that only reflects a lack of appreciation of lenzilumab's capability. IN MY OPINION.
Tell that to Gilead, who tried to enhance azacitidine by acquiring '47 Inc.' for $4.9B, for their magrolimab MAB.
But you can certainly count me in on wanting to see, not just an update, but regulatory recognition and approval of lenz. The issue isn't that management owes us an update, it's that regulators, somewhere in the world, owe Humanigen authorization and approval of lenz.